In addition, the serum of 8/22 (36%) people with CIS or MS also contained anti-EBV VCA IgM antibodies, which is considerably higher than the 3–6% rate of seropositivity demonstrated in other clinical settings (45). The gene discussed is CD40LG; the disease is in situ carcinoma.